Navigation Links
Isis Reports Financial Results and Highlights for Fiscal year 2007
Date:3/13/2008

bis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as its Ibis Biosciences subsidiary and its Regulus joint venture, and the therapeutic and commercial potential of the Company's technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve

assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are descri
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Every Friday afternoon at A ... in Southwest Michigan, patients and staff gather in the ... the rehabilitation program and to gain encouragement and inspiration ... , One by one, those patients who have completed ... their certificates and to share a bit about their ...
(Date:5/4/2015)... UK (PRWEB) May 04, 2015 During ... witness a 7.7% CAGR. Currently, the European and APAC ... world, while the North American probiotic market lags behind ... local population. , The North American probiotic market ... over 58%), followed by Canada and Mexico. The North ...
(Date:5/4/2015)... 04, 2015 The American Council ... Thomopulos, P.E., Chairman of Stanley Consultants , to ... of directors for a three-year term. , ACEC co-established ... the American Society of Civil Engineers (ASCE). A ... system for civil infrastructure called Envision. Launched in 2012, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Global ... innovative proofreading technologies, today announced that it will ... the Music City Center, in Nashville Tennessee, May ... the world's first true all-in-one we-based packaging inspection ... in the security of their brand copy and ...
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2
... LINDA, Calif., Feb. 2 Loma Linda ... "Baby-Friendly" designation over the weekend for its efforts ... skills needed to successfully initiate and continue breastfeeding ... in the Nation to be awarded this status. ...
... Pa., Feb. 2 Employers spend more than $13 billion ... - dubbed the world,s number one health threat by the ... are more prone to injury and accidents and incur higher ... a guidepost to help employers address this issue. Health ...
... The U.S. Department of Health and Human ... of interoperability standards developed by the Healthcare ... produces "Interoperability Specifications" - documents that harmonize and ... interoperability of electronic health records and help support ...
... Pet advocates are encouraging,pet owners to focus on their ... Month this February. And it appears more Americans ... saw claims,for illnesses related to oral-health increase 179 percent ... pet owners don,t place as much emphasis on dental ...
... the role of hormone use on the risk of ... progesterone increases the risk of both ductal and lobular ... "safe" period for the use of estrogen and progesterone; ... observed in long-term past users of hormone replacement therapy ...
... Factor in Improving Formulary Placement of Newer ... New Report from HealthLeaders-InterStudy and ... Feb. 2 HealthLeaders-InterStudy and Fingertip Formulary ... pharmacy directors expect to reimburse both Bristol-Myers ...
Cached Medicine News:Health News:LLUCH is First Children's Hospital in Nation to Receive 'Baby-Friendly' Designation 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:Pet Dental Claims Skyrocket 2Health News:Study identifies potential 'safe period' for hormone replacement use 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 3
(Date:5/4/2015)... , May 4, 2015 Bayer HealthCare (Bayer) ... Pharmaceuticals, Inc. (NASDAQ: ISIS ) on ISIS-FXI Rx, ... the prevention of thrombosis. Under the agreement Bayer will ... of high unmet medical need. As part of the ... profile of ISIS-FXI Rx in an appropriate patient ...
(Date:5/4/2015)... LOS ANGELES , May 4, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... phase 1b aldoxorubicin combination studies pairing aldoxorubicin with ... doses of gemcitabine or ifosfamide with escalating doses ... tolerated, and even at the lowest dose level ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
Medicine Products: